Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil for Cancer-Related Fatigue in High Grade Glioma
NCT01781468Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2013
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of armodafinil in cancer-related fatigue (CRF) (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Clinically Meaningful Improvement in Patient-reported Fatigue (Brief Fatigue Inventory) at 8 weeks. Started Jun 2013; status: completed.
02
Drugs
armodafinil
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT01781468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01781468.